Navigation Links
John Theurer Cancer Center researchers shed light on new multiple myeloma therapy
Date:7/25/2012

anced multiple myeloma, however, it has been shown to cause peripheral neuropathy in approximately 38 percent of treated patients with subcutaneous administration.

Phase II 004 Clinical Trial Results for Advanced Myeloma

Dr. Siegel and Dr. Vesole served as co-investigators on an 18-center, phase II open-label efficacy and safety clinical trial, also known as 004, of carfilzomib in combination with Bortezomib, another proteasome inhibitor. The study was published in the June 14th issue of Blood.

"We saw significant responses in patients considered more difficult to treat, including those with more advanced disease and poor prognoses," said Dr. Siegel, the senior author of the study. "Our results support the potential use of carfilzomib in this patient population."

The researchers enrolled 129 patients with multiple myeloma who had relapsed following one to three previous courses of treatment. Patients treated with bortezomib were excluded, as it is in the same drug class as carfilzomib and its use might make the effect of carfilzomib more difficult to determine. The study's primary endpoint was overall response rate. Researchers also measured patients' responses at various intervals as well as time to disease progression, and recorded reactions (adverse events) to treatment.

The most common adverse events in the study were fatigue (62 percent) and nausea (48.8 percent), while 17.1 percent of patients developed peripheral neuropathy, mostly Grades 1 and 2. Peripheral neuropathy, damage to nerves that fan out across the body from the brain and spinal cord, causes pain and other symptoms; lower grades have less severe symptoms. Peripheral neuropathy has been reported in 37-70 percent of myeloma patients receiving other commonly used drug therapies.

"Our myeloma team is leading the way in innovative research that makes promising therapies available to our patients, while also continually testing new
'/>"/>

Contact: Amy Leahing
aleahing@p4strategy.com
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Experts from John Theurer Cancer Center to participate in the AAMDSIF Patient and Family Conference
2. John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium
3. New probe provides vital assist in brain cancer surgery
4. Researchers find driver of breast cancer stem cell metastasis
5. Novel pig model may be useful for human cancer studies
6. Colonoscopy screening markedly reduces colorectal cancer incidence and death
7. A new route for tackling treatment-resistant prostate cancer
8. Antioxidants Might Help Cut Pancreatic Cancer Risk, Study Suggests
9. Young Cancer Patients Often Lack Support: Study
10. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
11. Tel Aviv University research links childhood obesity to cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... San Francisco, CA (PRWEB) , ... August 03, 2015 , ... ... MSHA, as the chief operating officer (COO) at CPMC. Hamila will start in her ... four hospital campuses. , Kownacki has worked at CPMC and Sutter Health for ...
(Date:8/3/2015)... ... 2015 , ... Code , an industry leader of image-based barcode reading ... Reader accessory that enables a wireless connection between the CR5000 and a ... of barcode reading applications with iPads, Galaxy Tabs, and many other products that lack ...
(Date:8/3/2015)... ... 03, 2015 , ... They know every second counts. And when it comes ... some of the best care in the nation. For the past two months, the ... blood clot removal time in the country. During the months of June and July, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to Monitor ... of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to ... , A cooperative agreement awarded by the U.S. Agency for International Development ...
(Date:8/3/2015)... ... 03, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today welcomed the announcement by OPKO Health that the US Food ... new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses ...
Breaking Medicine News(10 mins):Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... Human Resources continues to,be a big cost center, ... cost reductions and productivity improvements. So how can ... comprehensive HR metrics study by benchmarking leader Best Practices,LLC ... of performance,metrics for your key HR functions: Staffing, Benefits, ...
... Just six hours of instruction improved relationships with patients, ... -- New evidence suggests that a bit of theatrics ... is based on the experience of a small group ... of theater workshops and lectures led by university theater ...
... Today in Major Indian Newspapers Includes, Chart Comparing Cipla ... ... India, Sept. 6 As part of its,ongoing global campaign to ... Healthcare Foundation (AHF),has published a print advertisement in the form of ...
... forward,to Saturday, September 8,s Michigan Policy Summit as a ... education, women,s and,civil rights, labor and social justice organizations ... a common action agenda around the,issues of education, energy ... hangs in the balance," stated AFT Michigan,President David Hecker. ...
... Prime Therapeutics (Prime), a,thought leader in ... in Pharmaceutical Purchasing Standards SM (TIPPS SM),certification. ... the HR Policy Association,Pharmaceutical Coalition, an alliance ... initiative calls for adherence to nine drug ...
... Sept. 6 Par,Pharmaceutical Companies, Inc. (NYSE: PRX ... its 2006 Annual Report on Form 10-K. The,filing of ... to the work,involved in restating its consolidated financial statements ... Par intends to file its,Form 10-Q for the first ...
Cached Medicine News:Health News:End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver 2Health News:Theater Classes Help Docs' Bedside Manners 2Health News:Theater Classes Help Docs' Bedside Manners 3Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 2Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 3Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 4Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 5Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 6Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 7Health News:Prime Therapeutics Receives TIPPS Certification 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 3Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 4Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 5Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 6Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 7Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 8Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 9Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 10Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 11Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 12
(Date:8/3/2015)... , August 3, 2015 ... between biotech companies, military surgical research and ... therapies with regards to severe wound treatments ... enhancements for regenerative medicine and tissue-engineered skin ... partnerships and advancements in focus are Amarantus ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
(Date:8/3/2015)... -- Array BioPharma Inc. (NASDAQ: ARRY ) today ... year of its fiscal year ended June 30, ... Array, noted, "Binimetinib and encorafenib, two innovative oncology ... regulatory submissions in 2016. Additional data shared over ... cancer further validate the value of these programs ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... 27, 2011 Reportlinker.com announces that ... available in its catalogue: ... Market Outlook to 2017- Glucose Monitoring ... http://www.reportlinker.com/p0739472/United-States-Diabetes-Care-Devices-Market-Outlook-to-2017--Glucose-Monitoring-and-Insulin-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology United ...
... December 27, 2011 ReportsnReports adds ... in Latin America , to its store. This ... in terms of their attractiveness as pharmaceutical markets ... property, and pricing are examined. The report presents ...
Cached Medicine Technology:United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 10United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 11United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 12Latin America Emerging Pharmaceutical Markets - Argentina, Chile, Colombia, Peru, and Venezuela 2Latin America Emerging Pharmaceutical Markets - Argentina, Chile, Colombia, Peru, and Venezuela 3